SequelSEC

CITIUS ONCOLOGY, INC. CTOR

Pharmaceutical Preparations · CIK 0001851484 · Fiscal year ends 0930

AnnualQuarterlyTTM
Revenue
$1.49M
Fiscal year ended 2026-06-30
Operating income
-$8.72M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

CITIUS ONCOLOGY, INC. (CTOR) reported revenue of $1.49M and net income of -$8.92M for the fiscal year ended 2026-06-30. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from CITIUS ONCOLOGY, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

CITIUS ONCOLOGY, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-31
Revenue$1.49M$1.67M$3.94M
Cost of revenue$491.84K$328.88K$789.21K
Gross profit$1.00M$1.34M$3.15M
Operating income-$8.72M-$28.61M-$5.25M
Net income-$8.92M-$26.61M-$5.53M
Research & development$218.50K$1.08M$1.02M
Weighted-average diluted sharesshares 107.89Mshares 100.03Mshares 87.46M
Pretax income-$9.03M-$26.84M-$5.27M
Income tax expense-$107.35K-$231.21K$264.24K
Diluted EPS$-0.08$-0.27$-0.06
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$4.22M$23.63M$2.86M
Selling & marketingUnavailableUnavailableUnavailable

Balance

CITIUS ONCOLOGY, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-31
Cash & equivalents$16.56M$2.63M$7.30M
Total assets$112.09M$100.70M$109.97M
Current assets$42.71M$29.42M$37.15M
Total liabilities$71.71M$65.43M$51.56M
Current liabilities$58.79M$58.81M$44.71M
Total equity incl. NCI$40.38M$35.27M$58.41M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
Inventory$22.63M$22.66M$22.64M
Accounts receivable$686.24K$1.08M$4.05M
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$7.32M$8.88M$10.45M

Cash flow

CITIUS ONCOLOGY, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-31
Operating cash flow-$2.71M-$3.83M-$7.35M
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flow-$2.00M-$600.00K-$4.40M
Financing cash flow$18.64M-$231.20K$15.13M
Net change in cashUnavailableUnavailableUnavailable
Stock-based compensation$3.56M$3.53M$3.96M
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

CITIUS ONCOLOGY, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-31
Free cash flowUnavailableUnavailableUnavailable
Gross margin67.1%80.3%80.0%
Operating margin-583.5%-1716.2%-133.2%
FCF marginUnavailableUnavailableUnavailable
SBC / revenue238.4%211.5%100.3%
Current ratio0.73x0.50x0.83x
Revenue YoY growthUnavailableUnavailableUnavailable
Net margin-597.4%UnavailableUnavailable
R&D / revenue14.6%64.7%25.8%
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CTOR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-Q · Filed 2026-02-13View SEC filing
10-K · Filed 2025-12-23View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.